Title: Human Gut Bacteria Tailor Extracellular Vesicle Cargo for the Breakdown of Diet- and host-derived glycans
Dr. Feldman obtained his Ph.D. at the University of Buenos Aires, Argentina, under the supervision of Dr. Armando Parodi. After completing his postdoctoral training in Guy Cornelis and Markus Aebi labs in Switzerland, he joined the University of Alberta, in Edmonton, Canada, as an assistant professor. In 2015 he moved to the Department of Microbiology at the Washington University School of Medicine in St Louis, USA. The Feldman lab is interested in microbial glycobiology and bacterial pathogenesis. Dr. Feldman has pioneered the field of bacterial glycoengineering, which is a promising approach for the generation of novel bioconjugate vaccines. He has co-founded two companies (VaxAlta and Omniose) in this area. He is a world leader in studying the human pathogen Acinetobacter baumannii and the biogenesis of bacterial extracellular vesicles. Dr. Feldman is a fellow of the American Academy of Microbiology.
Title: Altered Glycosylation in Cancer Affects Cellular Receptor Tyrosine Kinases and Regulates Cancer Cell Sensitivity to Therapeutic Drugs.
Celso A Reis is the Head of the Glycobiology in Cancer group at i3S-Institute for Research and Innovation in Health, University of Porto, Portugal. He serves as a member of the Board of Directors of i3S and on the Board of IGO. He is a Professor at the Institute of Biomedical Sciences, University of Porto, and an invited Professor at the Faculty of Medicine of the University of Porto. Celso A Reis has published 227 peer-reviewed papers with over 15400 citations and with an H-index of 56 (Scopus). He is the author of several book chapters and patents. Currently, he leads an international multidisciplinary team working on glycobiology in human diseases focusing on cancer. His lab investigates the molecular mechanisms controlling glycosylation in cancer and the role of glycans during carcinogenesis and tumor progression. He has made several contributions to the development of novel strategies to improve cancer diagnosis, prognosis, and patient stratification. These include the studies on the role of glycosyltransferases regulating the biosynthesis of several glycans involved in cancer, such as those controlling critical steps on mucin-type O-glycosylation and N-glycosylation, with impact in cancer invasion and metastasis, as well as the tumor microenvironment.
Title: Protein-Carbohydrate Interactions in Infection and Cancer Biology
Dr. Ute Krengel studied Chemistry in Göttingen (Germany) and obtained her Ph.D. from the University of Heidelberg in 1991 (structure and molecular mechanism of p21ras). After positions in Toronto (Canada), Groningen (The Netherlands), and Gothenburg (Sweden), she moved to Oslo (Norway), where she has held a full Professorship since 2006. She is particularly interested in molecular mechanisms of diseases, including infectious diseases and cancer, focusing on receptor interactions and enzymes. She currently serves as the Norwegian Block Allocation Group for Synchrotron Research coordinator and as a Norwegian representative of the International Glycoconjugate Organization.
Title: Desialylation GlycoSwitch to Acutely Control Endocytosis
Professor Ludger Johannes is Research Director (DRE) at INSERM. He is a member of the Studienstiftung des Deutschen Volkes (German organization of the academically gifted), Boehringer Ingelheim Fonds, European Molecular Biology Organization (EMBO), and German Academy of Science — Leopoldina. At Institut Curie, he has been heading since 2001 the Traffic, Signaling, and Delivery Team, member of the excellence initiative Cell(n)Scale. Since January 2014, he has directed the Cellular and Chemical Biology unit. His research aims at establishing fundamental concepts of endocytosis and intracellular trafficking. The Johannes team has discovered the membrane trafficking interface between early endosomes and the Golgi apparatus, and demonstrated that lectin-induced glycolipid reorganization acts as a driving force in clathrin-independent endocytosis (termed the GlycoLipid-Lectin / GL-Lect hypothesis). The studies of the Johannes team have been published in highly visible international journals, including Cell and Nature. Between 2014-2020, he was the holder of an ERC advanced grant. He also aims at exploiting the discoveries of his team for the development of innovative cancer therapy strategies using the B-subunit of Shiga toxin (STxB) as a "pilot" for the delivery of therapeutic compounds to precise intracellular locations of dendritic cells for immunotherapy, and to tumors for targeted therapy.
Dr. Vered Padler-Karavani received her PhD in biochemistry from Tel Aviv University. She then did her postdoctoral training with Prof. Ajit Varki at The University of California, San Diego (UCSD) and subsequently established The Laboratory for Glycoimmunology at Tel Aviv University The George S. Wise Faculty of Life Sciences, Department of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research. Her research combines glycobiology, immunology, bio-nanotechnology, cancer research and xenotransplantation, and involves cutting edge technologies within these disciplines. She received several prestigious grants from the European Commission (Marie Curie, Health Consortium, ERC) to investigate various aspects of immunology of carbohydrates. With TRANSLINK health consortium (6 academic institutes, 5 hospitals and 3 companies from Israel, Italy, France, Spain, UK, Sweden, Canada and USA; https://cordis.europa.eu/project/id/603049), she investigated risk factors of animal-derived heart valve implants, in ~5,000 patients. Her research is currently focused on studying mechanisms of glycan immune recognition and responses in animal models and in humans, in vitro and in vivo. Particularly, the immunological basis of anti-carbohydrate antibodies and their implications on cancer and heart diseases, and on developing novel diagnostics and therapeutics for such diseases.
Title: A functional study of O-GlcNAcylation on RNA binding protein RBM14
Professor Won Ho Yang received his Ph.D. from Yonsei University, Seoul, Korea, in 2007. After postdoctoral work in the laboratory of Professor Jamey Marth at the UC Santa Barbara, he joined the Department of Systems Biology, Glycosylation Network Research Center, at Yonsei University as an Assistant Professor in 2019. His research interest is understanding the function of protein glycosylation in normal physiology and the pathogenesis of the disease.
Title: Labeling, Imaging and Proteomics of Brain Glycans
Dr. Xing Chen is currently a Changjiang Distinguished Professor and Dean of the College of Chemistry and Molecular Engineering at Peking University. He completed his bachelor’s degree in chemistry in 2002 from Tsinghua University and his Ph.D. in chemistry in 2007 from University of California, Berkeley, under Prof. Carolyn Bertozzi and Prof. Alex Zettl. He then joined the laboratory of Prof. Timothy Springer at Harvard Medical School as an LSRF postdoctoral fellow, where his research focused on structural immunology. Dr. Chen started as an Assistant Professor of Chemistry at Peking University in 2010 and was promoted directly to Full Professor with tenure in 2016. He is also affiliated with Center for Life Science (CLS) and Synthetic and Functional Biomolecule Center (SFBC) of Peking University. Some of his recent awards include ACS Horace S. Isbell Award (2021), Xplore Prize (2010), Tan Kah Kee Young Scientist Award (2020), Okeanos-CAPA Senior Investigator Award at the Chemical and Biology Interface (2019), CCS-RSC Young Chemist Award (2018), ACS David Y. Gin New Investigator Award (2016), IGO Young Glycoscientist Award (2015), and National Science Fund for Distinguished Young Scholars (2014). His current research interest focuses on chemical glycobiology.
Title: Galectins, Atg8ylation, and Stress Granules in Autophagy and Membrane Stress Response
Dr. Vojo Deretic is the department chair of the Department of Molecular Genetics and Microbiology at the University of New Mexico School of Medicine and the director of the NIH-funded Autophagy, Inflammation and Metabolism (AIM) Center of Biomedical Research Excellence. The AIM center aims to promote autophagy research nationally and internationally and to develop a cadre of junior faculty along with senior experts in this area to study fundamental mechanisms and how autophagy intersects with a broad spectrum of human disease and health states. He received his undergraduate, graduate, and postdoctoral education in Belgrade, Paris, and Chicago. Dr. Deretic’s main contributions to science come from studies by his team on the role of autophagy in infection, immunity, and inflammation. Recently, Dr. Deretic’s group developed the concept of a cellular system termed MERIT for coordinated membrane repair, removal, and replacement. This involves recognition of exposed glycoconjugates on damaged membranes, membrane repair, removal of membranes by autophagy, and replacement of membranous organelles through respective biogenesis programs.
Title: Regulation of the Biosynthesis of Glycopeptidolipids in Mycobacterium Abscessus
Dr. Guérardel is a senior researcher for CNRS (Lille University, France) and an Invited Professor at iGCORE (Gifu University, Japan). His research focuses on the structure-to-function relationships of complex carbohydrates, from microorganisms to higher eukaryotes, mostly in the context of host-pathogen interaction. His main objective is to understand how the glycans from both host and pathogen fine-tune the infectious process and how they may be used as diagnosis or therapeutic tools, with a keen interest in mycobacterial, fungus, and viral infections. To reach this goal, Dr. Guérardel integrates a wide range of scientific approaches, including synthetic chemistry, structural analysis using NMR spectroscopy and mass spectrometry, structural biology of proteins, and enzymology.
Title: Targeting Cancer-Associated Sialylation for Cancer Immunotherapy
Dr. Heinz Läubli received his M.D. and Ph.D. at the Institute of Physiology, University of Zürich (Switzerland). He is now an Assistant Professor and a Research group leader at the University of Basel and an Attending physician in the Division of Oncology, and Head of Glycobiology Research in the Department of Biomedicine, at the University Hospital Basel. Dr. Heinz’s research interests are to improve immunotherapy for cancer patients by using translational in vitro and in vivo tumor models, performing correlative analysis of patients treated with immunotherapy, and conducting early clinical interventional trials. His group has been studying the interaction between siaologlycans and their interaction with Siglec receptors on immune cells. It has demonstrated that this pathway can be targeted to augment T-cell stimulation and tumor control. His research goals also include the improvement of cancer immunotherapy by modifying glycans in the tumor microenvironment and glycans of cellular products for adoptive cell therapies, including genetically modified T cells.
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.